Innate Pharma SA (FR:IPH) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Innate Pharma SA has appointed Jonathan Dickinson as the new CEO and Chairman of the Executive Board, beginning November 1, 2024. Dickinson, who brings extensive biotech and pharmaceutical experience, succeeds interim CEO Hervé Brailly, who will remain in an advisory role to ensure a smooth transition. This leadership change is expected to drive the company’s innovative immuno-oncology pipeline forward, potentially impacting its stock performance.
For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.
